Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
MENS stock price ended at $2.05 on 星期五, after rising 0.00%
On the latest trading day May 08, 2026, the stock price of MENS rose by 0.00%, climbing from $2.09 to $2.05. Throughout the session, the stock experienced a volatility of 5.00%, with prices fluctuating between a daily low of $2.00 and a high of $2.10. Alongside this price increase, trading volume also rose by 2.1K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 39.2K shares were traded, amounting to a market value of approximately $155.8M.
MENS 技術面訊號
技術面訊號摘要
買入訊號 2
中性訊號 1
賣出訊號 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
MENS 目前顯示 2 個買入訊號與 4 個賣出訊號。該股票自 12:00 AM 以來一直處於 上升趨勢 狀態,在此期間價格總共變動了 --。整體而言,技術指標顯示中期後市趨勢為 Sell。